How to Screen New ADC Patent Publications for a Weekly Watchlist
A useful ADC patent monitor turns new publications into actions for IP, R&D, and BD teams. It removes acronym and background noise, confirms the ADC basis in the record, consolidates families, and separates patent assertions from independently verified scientific or commercial evidence.
Six of 24 retrieved WO publications contained explicit ADC composition, architecture, payload, or use-related subject matter. Family consolidation and the reconciled exclusion log were not completed.
Six ADC publications selected for family-level follow-up
Use the queue to assign deeper IP and R&D review—not to infer novelty, clinical value, ownership, or competitive importance.
Conjugate composition and payload-led disclosure
R&D: conjugation and evidence
Bispecific antibody and ADC architecture
R&D: format and internalization
Treatment-use and combination disclosure
BD: asset and combination context
Bispecific antibody, ADC, and composition
R&D: dual-target architecture
ADC composition and use disclosure
R&D: target and payload context
ADC composition and use disclosure
BD: applicant and asset linkage
Set the week, taxonomy, companies, family rule, baseline, and audience before retrieval.
What the completed weekly report should contain
The search set, screening queue, and final intelligence brief are different artifacts. A completed report keeps the reporting scope and method, reconciled screening funnel, family-consolidated watchlist, ADC architecture, claim or disclosure basis, weekly developments, opportunity and risk notes, and owner-assigned actions together.
The current Sample completes only retrieval and initial record-level ADC review.
How the two-pass screen works
Pass 1 removes obvious noise: unrelated acronyms, citation-only mentions, generic background text, and ADC appearing only as one option in an unbounded treatment list. Uncertain cases stay unresolved rather than being forced into a yes/no state.
Pass 2 checks the surviving record: retain it when ADC subject matter is central to a claimed composition, antibody format, linker or payload, conjugation method, treatment use, combination, or enabling disclosure. Record the evidence location and follow-up question. A title or abstract match alone is not enough when the brief promises claim-level relevance.
How Patsnap intelligence supports the monitor
The Skill packages the weekly scope, two-pass screen, family handling, evidence record, and audience-specific prioritization method. Patsnap Advanced Patent Search supports reproducible publication-date retrieval, while Patsnap Patent Briefing supports record-level review of bibliography, family, status, claims, descriptions, translations, and technical summaries.
This Sample did not use drug, clinical, news, deal, or market intelligence. Patent-stated efficacy, safety, or development benefits remain applicant assertions until independently verified.
Prepare, install, and run
Provide the inclusive dates and time zone, WO-only or expanded territorial scope, targets, payload or linker classes, antibody formats, indications, companies or named assets, family rule, prior-week baseline, and intended audience.
Create an ADC Patent Intelligence Weekly Report for new WO publications during [inclusive week and time zone]. Preserve the query, publication-date rule, ADC taxonomy, and family-counting rule. Screen every result in two passes; record each inclusion, exclusion, or unresolved reason; consolidate families; identify applicant, priority, ADC architecture, and claim/disclosure basis; then assign IP, R&D, and BD follow-up without treating patent statements as clinical proof.How each audience should use the result
IP teams verify families, applicants, priority, claims, prosecution, and status. R&D teams compare target, format, linker, payload, indication, and experiments without treating patent statements as validated performance. BD and strategy teams connect patent signals to separately verified company, asset, clinical, deal, and market evidence.
For this run, reconcile all 24 dispositions, consolidate the six records by family, and complete the applicant and weekly-change view before calling the queue a final intelligence brief.
Life-sciences decisions backed by linked evidence
The Skill packages monitoring scope, relevance rules, family consolidation, change triggers, and review ownership into a repeatable weekly report. The partial Sample preserves the unreconciled family boundary instead of presenting a retrieval set as a finished landscape.
Database foundationPatsnap connects drugs, targets, diseases, trials, literature, patents, biological sequences, and chemical structures in a linked life-sciences data foundation. Those relationships help preserve identity, provenance, development context, and competitive context across the analysis.
Patsnap OpenPatsnap Open makes selected data and tools available through APIs and MCP Servers for AI and enterprise workflows. Database coverage improves traceability, but experimental, clinical, regulatory, legal, and commercial validation remains necessary.
Review the claims and family context behind each signal
Use patent intelligence to inspect the bibliography, family, status, claims, descriptions, and translations of the records that survive screening.
Frequently asked questions
Why is this a screening queue rather than a final watchlist?
The run completed retrieval and initial claim/disclosure review, but the time zone, family consolidation, and reconciled exclusion log remain incomplete.
Why must the reporting time zone be stated?
It defines a reproducible weekly boundary. The recorded run did not preserve that metadata, so it must be confirmed before the interval is reused.
Does an ADC patent publication show clinical value?
No. It records a patent disclosure or claim signal. Clinical efficacy, safety, development status, and commercial importance require separate evidence.
Can the Skill monitor a narrower ADC scope?
Yes. Provide target aliases, payload or linker classes, antibody format, indication, company set, or named assets together with the weekly interval and family rule.
Disclosure: This article describes a Patsnap Skill and links to Patsnap Open. The monitoring output supports patent and competitive-intelligence triage; it is not a novelty, FTO, infringement, validity, ownership, clinical, partnering, or commercial opinion.
